Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,624 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cancer of the Neck Clear all
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Erythroplakia, Oral Leukoplakia
Interventions
Biopsy, Biospecimen Collection, Extended Release Metformin Hydrochloride, Placebo Administration
Procedure · Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Tucson, Arizona • San Diego, California • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Tumor
Interventions
belinostat, 5-Fluorouracil (5-FU)
Drug
Lead sponsor
Valerio Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 7, 2015 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Oral Decitabine, Durvalumab, 5' Azacitidine, Tremelimumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced May 21, 2026, 10:10 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cervical Cancer
Interventions
biopsy, computed tomography, positron emission tomography, fludeoxyglucose F 18
Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer, Renal Cell Carcinoma
Interventions
Durvalumab, Tremelimumab
Drug
Lead sponsor
Ludwig Institute for Cancer Research
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
6
States / cities
New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2022 · Synced May 21, 2026, 10:10 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp, Vehicle and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Inc.
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
14
States / cities
Phoenix, Arizona • Greenwood Village, Colorado • Delray Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms, Renal Neoplasms
Interventions
docetaxel, tariquidar, 99mTc-sestamibi imaging
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced May 21, 2026, 10:10 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 10:10 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Cancer of Head and Neck, Mucositis Oral, Pharyngeal Mucositis
Interventions
Ketamine Topical
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced May 21, 2026, 10:10 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Cancer
Interventions
protein expression analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Genetic · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 120 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced Squamous Tumors
Interventions
ABBV-711, Budigalimab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 10:10 PM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Cervical Cancer, Uterine Cancer
Interventions
18F fluciclovine, 18F fluciclovine PET
Drug · Device
Lead sponsor
Nghi Nguyen
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma, Locally Recurrent Laryngeal Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Squamous Cell Carcinoma, Recurrent Melanoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Unresectable Melanoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, Magnetic Resonance Imaging, Nivolumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
222
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 173 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 10:10 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck, Unresectable Head and Neck Squamous Cell Carcinoma
Interventions
Combination Treatment of PDS0101 and Pembrolizumab, Pembrolizumab Monotherapy
Combination Product · Drug
Lead sponsor
PDS Biotechnology Corp.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
28
States / cities
Phoenix, Arizona • Greenbrae, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 10:10 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Head and Neck Cancer, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
Interventions
Xevinapant, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
Nelfinavir (Viracept®) 1250 mg, Chemoradiation
Drug · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced May 21, 2026, 10:10 PM EDT
Suspended Not applicable Interventional
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Spondylolisthesis, Grade 1, Neurogenic Claudication
Interventions
Pedicle Lengthening Osteotomy with Altum® Device, Control
Device
Lead sponsor
Innovative Surgical Designs
Industry
Eligibility
40 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma of Unknown Primary, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVB Hypopharyngeal Carcinoma AJCC v8, Stage IVB Laryngeal Cancer AJCC v8, Stage IVB Lip and Oral Cavity Cancer AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Biological · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
252
States / cities
Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 193 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2024 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Ovarian Cancer, Urothelial Carcinoma, Non-small Cell Lung Cancer
Interventions
ONM-100
Drug
Lead sponsor
OncoNano Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced May 21, 2026, 10:10 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)
Interventions
Bexarotene (Targretin®), Erlotinib (Tarceva™)
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced May 21, 2026, 10:10 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced May 21, 2026, 10:10 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
Interventions
Zanidatamab
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
16
States / cities
Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced May 21, 2026, 10:10 PM EDT
Not listed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, gemcitabine hydrochloride
Drug
Lead sponsor
Hope Cancer Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced May 21, 2026, 10:10 PM EDT